FMP
Kairos Pharma, Ltd.
KAPA
AMEX
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
1.57 USD
-0.12 (-7.64%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. John S. Yu M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://kairospharma.comexchange
AMEX
Description
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
CIK
N/A
ISIN
US48301N1046
CUSIP
N/A
Address
2355 Westwood Blvd.
Phone
310-948-2356
Country
US
Employee
N/A
IPO Date
Sep 16, 2024
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
KAPA Financial Summary
CIK
-
Exchange
AMEX
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
US48301N1046
Country
US
Price
1.57
Beta
0
Volume Avg.
326.91k
Market Cap
20.17M
Shares
-
52-Week
1.22-4.0
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.48
P/B
-
Website
https://kairospharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KAPA News
It looks like there's no news available.
